Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 20;43(3):295–302. doi: 10.1016/j.htct.2020.06.014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Frist-line treatment (A) and response (B) in ≤5 and >65 years (n = 282).

Abbreviations. CYBORD: cyclophosphamide + bortezomib + dexamethasone; VTD: bortezomib + thalidomide + dexamethasone; CTD: cyclophosphamide + thalidomide + dexamethasone; TD: thalidomide + dexamethasone; MPV: melphalan + prednisone + bortezomib; MPT: melphalan + prednisone + thalidomide; MP: melphalan + prednisone; VAD: vincristine + doxorubicin + dexamethasone; DT-PACE: dexamethasone + thalidomide + cisplatin, doxorubicin + cyclophosphamide + etoposide; OR: overall response; CR: complete response; VGPR: very good partial remission; PR: partial remission; SD: stable disease; PD: progressive disease.